Matthew G Krebs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1216342/publications.pdf

Version: 2024-02-01

24 papers	3,560 citations	516215 16 h-index	676716 22 g-index

24 all docs	24 docs citations	24 times ranked	5547 citing authors

#	Article	IF	Citations
1	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusionâ€“Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100332.	0.6	15
2	Abstract CT198: Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study. Cancer Research, 2022, 82, CT198-CT198.	0.4	3
3	Abstract 2975: RAS precision medicine transatlantic partnership: Exploration of RAS and NF1 co-mutations in NSCLC. Cancer Research, 2022, 82, 2975-2975.	0.4	0
4	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusionâ€“Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 1253-1263.	0.8	74
5	Differential response rates in early-phase cancer clinical trials (EPCCT).. Journal of Clinical Oncology, 2021, 39, 3133-3133.	0.8	0
6	Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.. Journal of Clinical Oncology, 2021, 39, TPS3150-TPS3150.	0.8	2
7	Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials. Cancers, 2021, 13, 2443.	1.7	4
8	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research, 2021, 27, 5213-5224.	3.2	53
9	Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402.	0.8	320
10	Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC. Journal of Comparative Effectiveness Research, 2021, 10, 1271-1282.	0.6	12
11	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 261-270.	5.1	303
12	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology, 2020, 25, 61-66.	0.9	15
13	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncology, The, 2020, 21, 1155-1164.	5.1	274
14	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. Nature Cancer, 2020, 1, 437-451.	5.7	103
15	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	5.1	193
16	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nature Medicine, 2019, 25, 738-743.	15.2	202
17	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. British Journal of Clinical Pharmacology, 2018, 84, 1156-1169.	1.1	47
18	Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. Analyst, The, 2016, 141, 669-678.	1.7	95

#	Article	IF	Citations
19	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 115-122.e2.	1.0	43
20	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 6284-6294.	3.2	24
21	Molecular analysis of circulating tumour cellsâ€"biology and biomarkers. Nature Reviews Clinical Oncology, 2014, 11, 129-144.	12.5	535
22	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Medicine, 2014, 20, 897-903.	15.2	608
23	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. Journal of Thoracic Oncology, 2012, 7, 306-315.	0.5	411
24	Circulating tumour cells: their utility in cancer management and predicting outcomes. Therapeutic Advances in Medical Oncology, 2010, 2, 351-365.	1.4	224